BioCity's Late-Breaking Clinical Trial Presentation at ASN 2024
BioCity Biopharma is gearing up for a significant presentation at the upcoming ASN Kidney Week 2024, where it will share late-breaking clinical trial data on its ETA selective antagonist, SC0062. This event, anticipated to attract many professionals in nephrology, will take place over several days in the near future.
Highlighting the SC0062 Clinical Trial Data
With the abstract titled "SC0062, a New Selective Endothelin Receptor Type A Antagonist in IgA Nephropathy," BioCity will feature Dr. Hiddo Lambers Heerspink from the University Medical Center Groningen as the presenter. This detail alone raises expectations about the data's potential impact in the field of nephrology and chronic kidney disease (CKD).
Details of the Presentation
The presentation is part of an oral abstract session specifically devoted to late-breaking science, scheduled for October. Attendees can look forward to a thorough overview of the findings related to SC0062 during the designated time frame.
Breakthrough Therapy Designation and Ongoing Studies
SC0062 has received Breakthrough Therapy Designation (BTD) from China's National Medical Products Administration (NMPA) for treating IgA Nephropathy (IgAN) characterized by proteinuria. This designation highlights the drug's potential significance in this area of medical need.
2-SUCCEED Clinical Trial Overview
The randomized double-blind, placebo-controlled Phase 2 trial, known as 2-SUCCEED, has shown enthusiasm among researchers due to its clinically meaningful results and a solid safety profile. Notably, it has demonstrated a statistically significant reduction in proteinuria, which is vital for patients with IgAN. Currently, the study is also progressing in the diabetic kidney disease (DKD) cohort, with results anticipated shortly.
Global Clinical Development Plans for SC0062
Looking ahead, BioCity is making plans for Phase 3 clinical trials of SC0062 in both China and international markets. The aim is to secure regulatory approval for SC0062 not just for treating IgAN but also for chronic kidney disease (CKD).
About the Innovative SC0062 Treatment
SC0062 is considered a highly selective endothelin receptor type A antagonist, which sets it apart from non-selective alternatives in terms of safety and efficacy. Its unique properties suggest it could significantly reduce the progression of CKD while minimizing potential complications associated with non-selective ET antagonists.
Preclinical and Clinical Development Insights
Recent preclinical studies suggest that SC0062 could improve outcomes in conditions like acute kidney injury and CKD. In its Phase 1 study, it displayed favorable outcomes concerning safety and tolerability, without the fluid retention often linked with non-selective ET antagonists. Current ongoing trials are designed to solidify the drug's role in treating CKD and associated conditions.
Company Profile: About BioCity
Founded in December 2017, BioCity is a dedicated clinical-stage biopharmaceutical company focused on pioneering therapeutics for cancer and autoimmune disorders alongside CKD. With a solid pipeline that includes over ten innovative drug candidates ranging from small molecules to antibody-drug conjugates, they are committed to addressing pressing healthcare challenges.
BioCity's clinical development of SC0062 in Phase 2 and the planned Phase 3 studies underline its commitment to advancing meaningful treatments in nephrology. The company also boasts several ongoing projects in oncology, emphasizing their diversified medicinal research agenda.
Frequently Asked Questions
What is SC0062?
SC0062 is a selective antagonist designed to target endothelin receptor type A, showing promise for treating conditions like IgA Nephropathy and chronic kidney disease.
When will the clinical trial data for SC0062 be presented?
The late-breaking clinical trial data will be presented at the ASN Kidney Week 2024 scheduled for later this year.
What is the significance of the Breakthrough Therapy Designation?
The Breakthrough Therapy Designation from NMPA indicates that SC0062 is considered significant for patients needing effective treatments for IgA Nephropathy.
Who is presenting the clinical data for SC0062?
Dr. Hiddo Lambers Heerspink from the University Medical Center Groningen will present the data regarding SC0062 during the session.
What types of studies are ongoing for SC0062?
Currently, the 2-SUCCEED study is ongoing, exploring the efficacy and safety of SC0062 in patients with CKD across multiple cohorts.
